CDKN2A and pancreatic neoplasm: Human pancreatic cancers have a specific mutational signature that include near-ubiquitous activating mutations of the oncogene KRAS (K Rat Sarcoma virus) and the frequent inactivation of the tumor suppressors TP53 (Tumor Protein P53), SMAD4/DPC4 (SMAD family Member4/Deleted in Pacreatic Carcinoma 4) e CDKN2A (Cyclin-Dependent KiNase inhibitor 2A) [12].